SCYNEXIS Inc.
Scynexis, Inc. is a biotechnology company, which focuses on the treatment of fungal infections.

Sectors
Nasdaq
Toggle Chart Options
Range Dropdown
$ % Vol
Volume: 52.89M Avg. 65-Day: 1.2M
4,414% vs Average 2.4200 Day range 2.9700 1.1500 Week Range 4.0400
Key Data
% of Float Shorted 2.49
Average Volume 1.2M
The Performance of a
5 Day
62.88%
One Month
69.94%
Three Months
100.68%
Year to Date
88.46%
One Year
-24.81%
Analyst Ratings
Buy
Number of ratings 2 Full Ratings
MarketWatch Dow Jones
Health Care: Higher Inflation Hedging in Health Care Roundup
30th, 2023 at 4:11 p.m. ET
30.2023 at 3:46 pm. ET by Tomi Ilgore
Scynexis shares jump 60% after GSK licensing deal
30th, 2023 10:13 am ET
Biotech and Pharma Antifungal Maker Scynexis Stock soars after GSK Deal
30th, 2023 at 9 a.m. Barron's
Healthcare CDC Alarms About Deadly Fungus Six Things You Should Know.
22.2023 at 9:25 am. Barron's
Scynexis' stock price target is reduced to $15.00, from $22.50 by Ladenburg Thalmann
13th, 2022 7:53 am ET by Tomi Ilgore
Maxim Group has reduced the price target for Scynexis to $16 per share from $22
Nov. 17, 2020 at 8:50 am ET by Tomi Ilgore
Maxim Group has raised the price target for Scynexis to $22 from $17.
17th February 2021, 11:51 am ET by Tomi KILGORE
Maxim Group has reduced the price target for Scynexis to $15, down from $40.
21.2020 at 9:25 am. Tomi Kilgore
RBC: Some cheap biotech stocks could be bought out by investors
25 January 2016 at 1:31 pm Emma Court
Press Releases on Other News
Dow rises 100 points; Accelerate Diagnostics shares soar higher
30th, 2023 at 2 p.m. ET on Benzinga.com
Twelve Health Care Stocks Moved In Intraday Trading On Thursday
30th, 2023 at 12:31 pm ET on Benzinga.com ET on Benzinga.com
Why Bed Bath & Beyond Stocks are Trading Lower by 15%? What Other Stocks Moved In The Midday Session On Thursday?
30th, 2023 12:43 PM ET on Benzinga.com ET on Benzinga.com
Analysts offer insights on healthcare companies: Xoma and SCYNEXIS
30th, 2023 at 11 a.m. TipRanks.com
GSK Bets on Scynexis FDA-approved antifungal drug for over $500M in Bio Bucks
30th, 2023 at 11 a.m. ET on Benzinga.com
Warner Music layoffs: What you need to know about the latest job cuts
30th, 2023 at 10 a.m. InvestorPlace.com
Why is Scynexis stock up 69% today?
30th, 2023 10:26 am ET on InvestorPlace.com InvestorPlace.com
Twelve Health Care Stocks Moved In Wednesday's intraday session
1 at 12:31 pm ET on Benzinga.com ET on Benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
The 10 biggest stock gainers and losers of Monday's pre-market:
Dec. 30, 2020 at 12:02 pm. ET on Benzinga.com
Stocks that hit 52-week lows on Wednesday
Dec. 28, 2020 at 11:23 am ET on Benzinga.com ET on Benzinga.com
SCYNEXIS Return on Capital Employed Overview
SCYNEXIS Inc.
SCYNEXIS, Inc., is a biotechnology firm that develops novel triterpenoid oral and intravenous antifungals for the treatment invasive fungal infection, such as vulvovaginal Candida, invasive Aspergillosis, or invasive Candidiasis. The company was founded on November 4, 1998 by Scot Kevin Huber and Terry Eugene Marquardt. Its headquarters are in Jersey City, NJ.